Session: FRI 102-126-Hyperandrogenic Disorders and Menopause
Poster Board FRI-125
Methods: A comprehensive search of several online databases from each database’s earliest inception to August 2013. The databases included Ovid Medline In-Process & Other Non-Indexed Citations, Ovid MEDLINE, Ovid EMBASE, Ovid Cochrane Central Register of Controlled Trials, Ovid Cochrane Database of Systematic Reviews, and Scopus. Randomized trials of follow up ≥ 6 month were included if they compared MHT with placebo or no treatment and reported an effect size for outcomes.
Results: Meta-analysis from 43 randomized controlled trials showed no association between all cause-mortality was and MHT [risk ratio (RR) 0.99 (95% confidence interval 0.94-1.05)] with no significant interaction based on hormone type or pre-existing heart disease. No association was found between MHT use and mortality due to myocardial infarction (RR 1.04, 95%CI 0.87-1.23), breast cancer (RR 0.93, 95%CI 0.26-3.32) or stroke (RR 1.49, 95%CI 0.95-2.31). Postmenopausal women taking MHT with cancer other than breast cancer had increased cancer mortality (RR 1.34 95%CI 1.09-1.67) compared to placebo
Conclusion: Moderate to high quality evidence from randomized controlled trials suggests that MHT use is not associated with a significant effect on all-cause mortality, cardiovascular death or breast cancer death; but may increase the risk of other types of cancer death.
Nothing to Disclose: KB, KM, AA, BGC, FA, AMA, JZ, MM
*Please take note of The Endocrine Society's News Embargo Policy at https://www.endocrine.org/news-room/endo-annual-meeting
See more of: Abstracts - Orals, Poster Previews, and Posters